You are receiving this email because you signed up to receive email updates from Trading And Investment News. If you do not want to receive these emails anymore, please unsubscribe.

Chief Ai

‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

INVESTMENT HIGHLIGHTS

17.2x High End Target Returns EIS Approved - 30% Tax Relief from HMRC Supported by Innovate UK Government grant In collaboration with government-backed Medicine's Discover Catapult 43.2% Forecast Growth (CAGR) of the global AI healthcare market by 2032 (representing a $490 Bn market)

Our development has been commissioned by the UK Government via Innovate UK in collaboration with the Medicines Discovery Catapult.

Our revenue streams include Oncology, Cardiology, Diabetes, Drug Discovery & Biotech, Paas, Data Services and more. Disclaimer: Any person accessing the email and considering potential investment opportunities featured on the email should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This email should not be construed as advice or a personal recommendation to any prospective investor. This investment is only eligible to investors that can certify as high net worth or sophisticated.